PARTNERS

Linearx - Exhibition Partner Logo

Exhibition Partner

LineaRx™, an Applied DNA Sciences, Inc. company, delivers enzymatically-produced Linea™ DNA as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity and scalability to support the next generation of nucleic acid-based therapies. Produced using a proprietary, largescale polymerase chain reaction (“PCR”) based manufacturing platform, Linea DNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences.

www.linearxdna.com

4th Circular Self-Amplifying RNA Therapeutics Summit 2025

Exhibition Partner

Headquartered in Morrisville, NC, USA, Synoligo Biotechnologies is a Contract Research and Development Organization (CRDO) specialized in manufacturing complex and highly modified oligonucleotide for academic, biotech start-up and large pharmaceutical communities. Synoligo is a leading oligonucleotide manufacturing company providing high quality, cost-effective custom oligonucleotides at varying scales for research, diagnostic, and therapeutic applications.

www.synoligo.com

4th Circular Self-Amplifying RNA Therapeutics Summit 2025

Exhibition Partner

Vazyme is a global technology and service provider dedicated to the design, manufacture, and application of bioactive proteins. With outstanding product quality and extensive supply chain expertise, we are driving innovation in T7 polymerases to meet diverse RNA synthesis needs, and are able to self-develop and produce dsRNA residue detection kits. Our GMP-grade mRNA tool enzymes and quality control kits ensure safety and efficacy, accelerating mRNA vaccine/drug R&D and advancing projects to clinical trials.

www.vazymeglobal.com

Arcalis

Event Partner

ARCALIS is a CDMO specializing in mRNA medicines and vaccines. Founded by Axcelead and Arcturus Therapeutics, we established a GMP mRNA drug substance facility in Japan in 2023. In 2024, we achieved the worlds first commercial production of a self-amplifying mRNA vaccine against COVID-19. With expertise in mRNA development and manufacturing, we support clients from early-stage research to commercial production across infectious diseases, rare diseases, oncology, regenerative medicine, and genome-editing therapies.

www.corp.arcalis.co.jp/en/

Interested in Partnering?

I’m here to help and happy to set up a call so we can discuss your commercial objectives within the RNA space and establish whether partnering with this meeting aligns with your strategy.